股票市场 | 中国生物制药：正大天晴加强与GSK独家战略合作
2026-07-08 08:43:04
据明报报道，中国生物制药（1177）宣布，其附属公司正大天晴药业进一步加强与葛兰素史克（GSK）于5月份达成的独家战略合作，推动两款呼吸领域重磅创新药物惠及更多中国患者。
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
中国6月乘用车销量下滑 出口缓冲跌势Next article：
地缘政治 | 特朗普：与伊朗人不是一路人
